Quantifying the Contribution of Defective Ribosomal Products to Antigen Production: A Model-Based Computational Analysis

Antigenic peptides (epitopes) presented on the cell surface by MHC class I molecules derive from proteolytic degradation of endogenous proteins. Some recent studies have proposed that the majority of epitopes stem from so-called defective ribosomal products (DRiPs), i.e., freshly synthesized proteins that are unable to adopt the native conformation and thus undergo immediate degradation. However, a reliable computational analysis of the data underlying this hypothesis was lacking so far. Therefore, we have applied kinetic modeling to derive from existing kinetic data (Princiotta et al. 2003, Immunity 18, 343–354) the rates of the major processes involved in the cellular protein turnover and MHC class I-mediated Ag presentation. From our modeling approach, we conclude that in these experiments 1) the relative share of DRiPs in the total protein synthesis amounted to ∼10% thus being much lower than reported so far, 2) DRiPs may become the decisive source of epitopes within an early phase after onset of the synthesis of a long-lived (e.g., virus derived) protein, and 3) inhibition of protein synthesis by the translation inhibitor cycloheximide appears to be paralleled with an instantaneous decrease of protein degradation down to ∼1/3 of the normal value.

[1]  P. Kloetzel,et al.  The proteasome and MHC class I antigen processing. , 2004, Biochimica et biophysica acta.

[2]  Jacques Neefjes,et al.  A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. , 2004, Immunity.

[3]  R. May Uses and Abuses of Mathematics in Biology , 2004, Science.

[4]  A. Goldberg Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[5]  J. Yewdell,et al.  Making sense of mass destruction: quantitating MHC class I antigen presentation , 2003, Nature Reviews Immunology.

[6]  Bjoern Peters,et al.  Identifying MHC Class I Epitopes by Predicting the TAP Transport Efficiency of Epitope Precursors , 2003, The Journal of Immunology.

[7]  Shu-Bing Qian,et al.  Quantitating protein synthesis, degradation, and endogenous antigen processing. , 2003, Immunity.

[8]  A. Goldberg,et al.  The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. , 2003, Immunity.

[9]  A. Goldberg,et al.  The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8–9 residues , 2002, Nature Immunology.

[10]  N. Shastri,et al.  ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum , 2002, Nature.

[11]  A. Ciechanover,et al.  Ubiquitin‐mediated degradation of cellular proteins in health and disease , 2002, Hepatology.

[12]  M. Buchmeier,et al.  Cutting Edge: Neosynthesis Is Required for the Presentation of a T Cell Epitope from a Long-Lived Viral Protein1 , 2001, The Journal of Immunology.

[13]  A. Goldberg,et al.  26S proteasomes and immunoproteasomes produce mainly N‐extended versions of an antigenic peptide , 2001, The EMBO journal.

[14]  A. Varshavsky,et al.  Detecting and measuring cotranslational protein degradation in vivo. , 2000, Science.

[15]  J. Neefjes,et al.  The major substrates for TAP in vivo are derived from newly synthesized proteins , 2000, Nature.

[16]  Jonathan W. Yewdell,et al.  Rapid degradation of a large fraction of newly synthesized proteins by proteasomes , 2000, Nature.

[17]  Hans-Georg Rammensee,et al.  Perfect use of imperfection , 2000, Nature.

[18]  M. Montoya,et al.  Intracellular rate-limiting steps in MHC class I antigen processing. , 1999, Journal of immunology.

[19]  M. Ruiz-Echevarría,et al.  Should we kill the messenger? The role of the surveillance complex in translation termination and mRNA turnover , 1999, BioEssays : news and reviews in molecular, cellular and developmental biology.

[20]  J. Yewdell,et al.  Intracellular Localization of Proteasomal Degradation of a Viral Antigen , 1999, The Journal of cell biology.

[21]  H. Jäck,et al.  Cycloheximide, a New Tool to Dissect Specific Steps in ER-Associated Degradation of Different Substrates , 1999, Biological chemistry.

[22]  W Keilholz,et al.  Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  F. Studier,et al.  Pausing and termination by bacteriophage T7 RNA polymerase. , 1998, Journal of molecular biology.

[24]  D. Wolf,et al.  Yeast cycloheximide-resistant crl mutants are proteasome mutants defective in protein degradation. , 1997, Molecular biology of the cell.

[25]  Alexei F. Kisselev,et al.  Processive Degradation of Proteins and Other Catalytic Properties of the Proteasome from Thermoplasma acidophilum* , 1997, The Journal of Biological Chemistry.

[26]  A. Varshavsky,et al.  The N-end rule: functions, mysteries, uses. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Yewdell,et al.  Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? , 1996, Journal of immunology.

[28]  A. Goldberg,et al.  Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. , 1995, Journal of immunology.

[29]  E. Pamer,et al.  Efficiency of MHC class I antigen processing: a quantitative analysis. , 1994, Immunity.

[30]  J. Bennink,et al.  RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes , 1992, The Journal of experimental medicine.

[31]  J. Drake A constant rate of spontaneous mutation in DNA-based microbes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Amenta,et al.  Inhibition of basal protein degradation in rat embryo fibroblasts by cycloheximide: Correlation with activities of lysosomal proteases , 1978, Journal of cellular physiology.

[33]  K. Wildenthal,et al.  Reduction by cycloheximide of lysosomal proteolytic enzyme activity and rate of protein degradation in organ-cultured hearts. , 1976, Biochimica et biophysica acta.

[34]  M. Wibo,et al.  Protein degradation in cultured cells. The effect of fresh medium, fluoride, and iodoacetate on the digestion of cellular protein of rat fibroblasts. , 1973, The Journal of biological chemistry.

[35]  G. Yagil,et al.  Does cycloheximide interfere with protein degradation? , 1969, Biochemical and biophysical research communications.

[36]  Kees Jalink,et al.  Peptide diffusion, protection, and degradation in nuclear and cytoplasmic compartments before antigen presentation by MHC class I. , 2003, Immunity.

[37]  N. Shastri,et al.  Producing nature's gene-chips: the generation of peptides for display by MHC class I molecules. , 2002, Annual review of immunology.

[38]  A. Varshavsky,et al.  Felix Hoppe-Seyler Lecture 2000. The ubiquitin system and the N-end rule pathway. , 2000, Biological chemistry.

[39]  L. Marzella,et al.  Regulation of intracellular protein degradation with special reference to lysosomes: role in cell physiology and pathology. , 1994, International review of experimental pathology.

[40]  A. Goldberg,et al.  Intracellular protein degradation in mammalian and bacterial cells: Part 2. , 1976, Annual review of biochemistry.

[41]  A. Goldberg,et al.  Intracellular protein degradation in mammalian and bacterial cells. , 1974, Annual review of biochemistry.